Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma - Top-Institutions - MDSpire

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

By
Luisina María Solernó
Candela Llavona
Zahira Yasmine Saud
Mariana Carolina Onassis
María Florencia Gottardo
Martín Manuel Ledesma
Daniel Fernando Alonso
Juan Garona
July 1, 2026
0 min

Frontiers In Medicine

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Gynecologic Oncology Group

Philadelphia, PA
Key Differentiators
- Oncology
#2

European Society for Medical Oncology (ESMO)

Brussels, Belgium
Key Differentiators
- Oncology
#3

National Surgical Adjuvant Breast and Bowel Project

Pittsburgh, PA
Key Differentiators
- Oncology
#4

NRG Oncology

Philadelphia, PA
Key Differentiators
- Oncology
#5

University of Arizona Cancer Center

Tucson, AZ
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Medicine

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

by Luisina María Solernó, Candela Llavona, Zahira Yasmine Saud, Mariana Carolina Onassis, María Florencia Gottardo, Martín Manuel Ledesma, Daniel Fernando Alonso, Juan Garona
July 1, 2026

Related Content

Frontiers In Medicine

Distinct trajectories of low anterior resection syndrome following ileostomy reversal

by Xuena Zhang, Qingyu Meng, Jingru Wang, Simeng Jiang, Zhongtao Tian, Zihan Fan, Tong Wang, Wenbo Niu
June 30, 2026

Jama Network Open

Human Papillomavirus–Related Cancer in People With HIV and Solid Organ Transplant Recipients

Frontiers In Oncology

Ferroptosis in chemotherapy resistance and resensitization in breast cancer: a systematic review of preclinical evidence and translational implications

by Kezhen Shen, Heng Zhang, Lei Cai
July 1, 2026